Semax | ACTH 4-10 Analogue

Research Overview

Semax is a synthetic heptapeptide analogue of ACTH 4-7 (Met-Glu-His-Phe-Pro-Gly-Pro), developed in Russia and studied extensively in neurological research models.

Published research has examined Semax’s interactions with melanocortin receptors, its influence on BDNF expression in animal models, and its neuroprotective properties in rodent models of ischemia and neurodegeneration. It has been used in clinical settings in Russia for neurological conditions, though it is not approved by the FDA.

Select Published Research

Dolotov OV et al. (2006). “Semax, an analogue of ACTH 4-7, regulates BDNF and trkB expression in the rat hippocampus.” Brain Research.
Grigoriev VV et al. (2016). “Semax effects on neuropeptide receptors.” Neurochemistry International.

All referenced studies were conducted in animal models or in vitro. These citations do not constitute claims of human efficacy or safety.

Specifications

Format: Lyophilized powder
Purity: >98% verified by HPLC and mass spectrometry
Storage: −20°C lyophilized. Reconstituted: 4°C, use within 14 days.
Source: Domestically synthesized

Certificate of Analysis

Third-party COA available in the Lab Results tab above.